Science

Apr 28, 2025, 14:36

Myeloma Paper of the Day, April 28th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Study of real-world clinical practice around AL amyloidosis in the United States finds most patients received 2 or more lines of treatment; 1/3 1st line patients had heme response; median PFS was 41.4 months, EFS 24.4 months.”

“Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice”

Authors: Sophia Li, Anita D’Souza, Suzanne Lentzsch, Faiza Zafar, Irina Pivneva, Talissa Watson, Annie Guerin, Shaji Kumar.

More posts featuring Robert Orlowski.

AL Amyloidosis Anita D'Souza Annie Guerin cancer Faiza Zafar Irina Pivneva Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Shaji Kumar Sophia Li Suzanne Lentzsch Talissa Watson

Yelena Janjigian shares immunotherapy trial results on cancer recurrence in MMRd patients at AACR 2025 - MSKCC

Top Growing Medical Universities in the Post-Soviet Region – BIGR 2025 Edition

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab

10 Caring Notes from Pope Francis on Healthcare

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma